Skip to content
Open access

From patient-reported outcome scores to clinical meaning: defining thresholds for clinical importance for the EORTC QLQ-PR25 questionnaire for patients with prostate cancer.

Oct 2026 · Radiotherapy and Oncology · Vol 225, pp. 111817 · 0 citations · 31 references
Medicine

TL;DR

This study provides the first TCIs for a questionnaire assessing health-related quality of life in patients with PCa, and may improve interpretation of individual patient scores, support symptom screening and clinical decision-making, and facilitate the definition of clinically meaningful outcomes in clinical research.

Abstract

Background

AND

Purpose

Interpretation of patient-reported outcome scores remains challenging. Thresholds for clinical importance (TCIs) can facilitate score interpretation at the individual-patient level. We aimed to establish TCIs for the EORTC QLQ-PR25 to improve the interpretation of prostate cancer (PCa)-specific patient-reported outcomes in clinical practice and research.

Methods

In this prospective multicentre study, 261 patients with PCa from seven countries completed the EORTC QLQ-PR25 and anchor items assessing limitations in daily life, need for help/care, and worries caused by the respective symptom or problem. Receiver operating characteristic analyses were used to derive TCIs for the QLQ-PR25 scales, using a binary criterion for clinical importance based on the anchor items. Sensitivity analyses explored threshold robustness across patient subgroups.

Results

For five of the six QLQ-PR25 scales, ROC analyses showed acceptable to excellent discrimination, with AUC values ranging from 0.74 to 0.90. The corresponding TCIs showed sensitivity values between 0.62 and 0.88 and specificity values between 0.48 and 0.98. No meaningful threshold could be established for sexual activity (AUC = 0.48).

Conclusions

This study provides the first TCIs for a questionnaire assessing health-related quality of life in patients with PCa. These thresholds may improve interpretation of individual patient scores, support symptom screening and clinical decision-making, and facilitate the definition of clinically meaningful outcomes in clinical research.

Read PDF

Similar papers

Open access Sep 2026

Validation for use in Colombia of the EORTC QLQ–THY34 questionnaire to measure quality of life in patients with thyroid cancer

Although survival after thyroid cancer is favorable, many patients experience persistent symptoms and concerns that affect health-related quality of life (HRQoL). This study evaluated the measurement properties of the Colombian Spanish EORTC QLQ-THY34 in patients with thyroid cancer. 500 adults treated at a national on...

Laura Johanna Piña Jaramillo, Diana Isabel Cuéllar Rivera, A. A. Cuéllar Cuéllar et al. · 0 citations
Open access Oct 2026

EORTC QLQ-C30 symptom components and their functional correlates during adjuvant chemotherapy for early breast cancer: a multivariate analysis. Data from GEICAM/2003-02 study

Understanding how multiple symptoms jointly impact functioning is essential for interpreting patient-reported outcomes (PROs) in oncology. We aimed to characterize the main dimensions underlying change-from-baseline (CFB) in symptom scores during adjuvant chemotherapy for early breast cancer, and to examine their assoc...

Andrea Blasco, R. Pastor-Barriuso, P. Zamora-Auñón et al. · 0 citations
Open access Oct 2026

Validity and responsiveness of Patient-reported outcomes Common Terminology Criteria for Adverse Events in the ovarian cancer cohort of the FICOG VIP study

Use of patient-reported outcomes (PROs) is recommended by regulatory authorities for improving patient care. A multicenter Italian study tests the psychometric properties of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) across cancer types in Italy. Here t...

Alice Bergamini, P. Gargiulo, M. Iacovino et al. · 0 citations
Review Open access Sep 2026

Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)

Background Metastatic breast cancer (MBC) remains a treatable, but incurable disease. Anti-cancer treatments and supportive therapies aim to control disease, prolong survival, ameliorate physical symptoms and improve quality of life (QoL). Currently, no validated MBC-specific patient-reported outcome measures exist, an...

C. Bedding, K. Absolom, K. Pogoda et al. · 0 citations
Review Open access Sep 2026

When do we need to take action? Cut-off values for the hamburg inventory for measuring quality of life in oncological patients (HELP-6)

Results of patient-reported outcome measurements need to be comprehensible and conclusive for a successful integration into treatment in cancer care. The aim of this study was to determine cut-off values for the recently developed “Hamburg Inventory for Measuring Quality of Life in Oncological Patients-6” (HELP-6), a s...

Theresa Schrage, M. Görlach, C. Betz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.